SCHEMBL24726792

SCHEMBL24726792

CCCCC[C@@H](O)/C=C/[C@H]1O[C@@H]2C[C@@H](O2)[C@@H]1C/C=C\CCCC(=O)O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.73
KMT2A Q03164 2/20 0.73
PTGFR P43088 3/20 0.67
TBXA2R P21731 6/20 0.65
ALDH1A1 P00352 5/20 0.65
LMNA P02545 5/20 0.65
PTGER4 P35408 3/20 0.65
SLCO2A1 Q92959 2/20 0.65
PTGER1 P34995 2/20 0.65
PTGER3 P43115 2/20 0.65
PTGDR Q13258 1/20 0.65
PTGDR2 Q9Y5Y4 1/20 0.59
HPGD P15428 4/20 0.57
ABCC4 O15439 1/20 0.57
PTGER2 P43116 2/20 0.54
PTGIR P43119 2/20 0.54
TSHR P16473 2/20 0.54
MAPK1 P28482 2/20 0.54
NR1I2 O75469 1/20 0.54
ESR1 P03372 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2512105 1.00 MEN1 (0.73) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL25710278 1.00 MEN1 (0.73) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL22168569 1.00 MEN1 (0.73) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL34165 1.00 MEN1 (0.73) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL2512107 1.00 MEN1 (0.73) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL10721021 0.99 MEN1 (0.72) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL9037070 0.93 MEN1 (0.65) MEN1KMT2APTGFRTBXA2RALDH1A1
Imidazole SCHEMBL10918367 0.89 MEN1 (0.59) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL1782277 0.87 MEN1 (0.58) MEN1KMT2APTGFRTBXA2RALDH1A1
SCHEMBL24855289 0.87 MEN1 (0.55) MEN1KMT2APTGFRTBXA2RALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220281797-A1 KEY INTERMEDIATE FOR SYNTHESIS OF PROSTAGLANDIN COMPOUND AND PREPARATION METHOD THEREOF SHENZHEN CATALYS TECHNOLOGY CO., LTD (CN) 2022-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281797-A1 KEY INTERMEDIATE FOR SYNTHESIS OF PROSTAGLANDIN COMPOUND AND PREPARATION METHOD THEREOF PTGES, PTGIS, PTGES2 MEN1 3136/4885KMT2A 4072/4885PTGFR 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.